Class 2 Medicines Recall: Class 2 Medicines Recall: Aventis Pharma Limited (t/a Sanofi), Stemetil 5mg/5ml Syrup, EL(22)A/41
Sanofi is recalling all batches of Stemetil 5mg/5ml Syrup as a precautionary measure due to the identification of N-nitrosomethylphenylamine (NMPA) above the acceptable limit.
|Batch Number||Expiry Date||Pack Size||First Distributed|
|0032||Feb 2023||100ml||17th Sep 2020|
|0033||Aug 2023||100ml||26th May 2021|
|0034||Sep 2024||100ml||14th Dec 2021|
|0035||Feb 2025||100ml||04th May 2022|
Active Pharmaceutical Ingredient: Prochlorperazine mesilate
Brief description of the problem
Sanofi is recalling all batches of the above product as a precautionary measure due to the identification of N-nitrosomethylphenylamine (NMPA) above the acceptable limit. Nitrosamines may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time.
Advice for healthcare professionals
Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
Healthcare professionals should advise patients undergoing treatment not to discontinue Stemetil Syrup without consulting with their prescriber. If this medicine was abruptly withdrawn, there is a possibility of the return of symptoms for which Stemetil Syrup was prescribed, and more rarely, withdrawal reactions such as nausea, vomiting, insomnia and movement disorders.
Based on the available data, there is no immediate risk to patients who have been taking this medication. Patients should be advised to discuss any questions or concerns with their prescribing healthcare professional.
Advice for patients
- Stemetil Syrup should not be stopped without talking to your prescriber. Based on current evidence, there is no immediate risk to patients who have been taking this medication.
- However, the Marketing Authorisation Holder will be stopping further supply of Stemetil Syrup following laboratory test results demonstrating excess levels of a chemical impurity that may potentially increase the risk of cancers if taken for a long time.
- Your prescriber should review your treatment and consider switching to a suitable alternative going forward.
Company contacts and further information
For more information or medical information please contact: firstname.lastname@example.org
Phone number: 0800 035 25 25
For full information: https://assets.publishing.service.gov.uk/media/633d6ff18fa8f52a5e20 4713/EL_22_A41.pdf